Effect of Thrombocytopenia on Outcomes Following Treatment With Either Enoxaparin or Unfractionated Heparin in Patients Presenting With Acute Coronary Syndromes

American Journal of Cardiology

Volumn 100, Issue 12, 2007, Pages 1734-1738

  Yeh, Robert W ^a   Wiviott, Stephen D ^b   Giugliano, Robert P ^b   Morrow, David A ^b   Shui, Amy ^b   Qin, Jie ^b   Scirica, Benjamin ^b   Bradner, James E ^c   Jang, Ik Kyung ^d   Gibson, C Michael ^c   Antman, Elliott M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REVASCULARIZATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANTS; COMORBIDITY; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RECURRENCE; THROMBOCYTOPENIA;

EID: 37049026384     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.07.036     Document Type: Article

References (13)

1. Harrington R.A., Sane D.C., Califf R.M., Sigmon K.N., Abbottsmith C.W., Candela R.J., Lee K.L., and Topol E.J. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. J Am Coll Cardiol 23 (1994) 891-898
2. Berkowitz S.D., Sane D.C., Sigmon K.N., Shavender J.H., Harrington R.A., Tcheng J.E., Topol E.J., and Califf R.M. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 32 (1998) 311-319
3. Eikelboom J.W., Anand S.S., Mehta S.R., Weitz J.I., Yi C., and Yusuf S. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) study. Circulation 103 (2001) 643-650
4. McClure M.W., Berkowitz S.D., Sparapani R., Tuttle R., Kleiman N.S., Berdan L.G., Lincoff A.M., Deckers J., Diaz R., Karsch K.R., et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 99 (1999) 2892-2900
5. Nikolsky E., Sadeghi H.M., Effron M.B., Mehran R., Lansky A.J., Na Y., Cox D.A., Garcia E., Tcheng J.E., Griffin J.J., Stuckey T.D., et al. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 96 (2005) 474-481
6. Merlini P.A., Rossi M., Menozzi A., Buratti S., Brennan D.M., Moliterno D.J., Topol E.J., and Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 109 (2004) 2203-2206
7. Berkowitz S.D., Stinnett S., Cohen M., Fromell G.J., Bigonzi F., and ESSENCE Investigators. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol 88 (2001) 1230-1234
8. Greinacher A., Eichler P., Lietz T., and Warkentin T.E. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 106 (2005) 2921-2922
9. Antman E.M., McCabe C.H., Gurfinkel E.P., Turpie A.G., Bernink P.J., Salein D., Bayes De Luna A., Fox K., Lablanche J.M., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 100 (1999) 1593-1601
10. Williams R.T., Damaraju L.V., Mascelli M.A., Barnathan E.S., Califf R.M., Simoons M.L., Deliargyris E.N., and Sane D.C. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107 (2003) 2307-2312
11. Mascelli M.A., Deliargyris E.N., Damaraju L.V., Barnathan E.S., Califf R.M., Simoons M.L., and Sane D.C. Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes. J Thromb Thrombol 18 (2004) 171-175
12. Chilver-Stainer L., Lammle B., and Alberio L. Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thromb Haemost 91 (2004) 276-282
13. Pena de la Vega L., Miller R.S., Benda M.M., Grill D.E., Johnson M.G., McCarthy J.T., and McBane II R.D. Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin Proc 80 (2005) 995-1000